(Z)-3-[2-(Carbazol-2-yloxy)-1-fluoroethylidene]quinuclidine hydrochloride | 182961-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (Z)-3-[2-(Carbazol-2-yloxy)-1-fluoroethylidene]quinuclidine hydrochloride
• 英文别名: 2-[(2Z)-2-(1-azabicyclo[2.2.2]octan-3-ylidene)-2-fluoroethoxy]-9H-carbazole;hydrochloride
• CAS: 182961-13-3
• 化学式: C₂₁H₂₁FN₂O*ClH
• 分子量: 372.87
• InChiKey: JWXYVHMBPISIJQ-LTRPLHCISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.07
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  28.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• NOVEL QUINUCLIDINE DERIVATIVES HAVING TRICYCLIC FUSED HETERO RING
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0812840A1

  公开（公告）日：1997-12-17

  A quinuclidine derivative represented by the following general formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, which has strong squalene synthase inhibiting activity and is useful as a cholesterol lowering agent without causing side effects. (Symbols in the formula represent the following meanings; R1: a hydrogen atom, a halogen atom or a lower alkyl group, R2: a hydrogen atom, a hydroxyl group or a lower alkoxy group, : a single bond or a double bond, with the proviso that R2 does not exist when is a double bond, X and Y: the same or different from each other and each represents a bond, an oxygen atom (-O-), a carbonyl group (-CO-), a group represented by the formula -S(O)p- or a group represented by the formula -NR3-, p: 0, 1 or 2, R3: a hydrogen atom or a lower alkyl group which may have a substituent, A: a saturated or unsaturated lower alkylene group, a group of the formula -(CH2)mZ(CH2)n- or a group of the formula -(CH2)mZ(CH2)nCR4=, Z: an oxygen atom (-O-), a group of the formula -S(O)q-, a carbonyl group (-CO-) or a group of the formula -NR5-, R4: a hydrogen atom, a halogen atom or a lower alkyl group, R5: a hydrogen atom or a lower alkyl group, m and n: the same or different from each other and each is 0 or an integer of 1 to 5, m + n: an integer of 1 to 5 q: 0, 1 or 2, with the proviso that, when either one of X and Y is a bond, A is a group represented by the formula -(CH2)mZ(CH2)nCR4=.)

  一种由以下通式（I）代表的喹烯酮衍生物、其药学上可接受的盐、其水合物或其溶液，该衍生物具有很强的角鲨烯合成酶抑制活性，可用作降低胆固醇的药物，且不会产生副作用。 (式中符号代表以下含义； R1：氢原子、卤素原子或低级烷基、 R2：氢原子、羟基或低级烷氧基、 R2：单键或双键，但 R2 为双键时不存在、 X和Y：彼此相同或不同，各自代表一个键、一个氧原子（-O-）、一个羰基（-CO-）、一个由式-S(O)p-代表的基团或一个由式-NR3-代表的基团、 p:0、1 或 2、 R3：氢原子或可带有取代基的低级烷基、 A：饱和或不饱和低级亚烷基、式-(CH2)mZ( )n-或式-( )mZ( )nCR4=的基团、 Z：氧原子（-O-）、式-S(O)q-的基团、羰基（-CO-）或式-NR5-的基团、 R4：氢原子、卤素原子或低级烷基、 R5：氢原子或低级烷基、 m 和 n：相同或互不相同，各自为 0 或 1 至 5 的整数、 m+n：1 至 5 的整数 q：0、1 或 2、 但条件是，当 X 和 Y 中任何一个是键时，A 是由式-( )mZ( )nCR4=代表的基团。）
• Production of carotenoids in oleaginous yeast and fungi
  申请人：Bailey Richard

  公开号：US20070015237A1

  公开（公告）日：2007-01-18

  The present invention provides systems for producing engineered oleaginous yeast or fungi that express carotenoids
• PRODUCTION OF CAROTENOIDS IN OLEAGINOUS YEAST AND FUNGI
  申请人：Bailey Richard B.

  公开号：US20110039299A1

  公开（公告）日：2011-02-17

  The present invention provides systems for producing engineered oleaginous yeast or fungi that express carotenoids.
• RETT SYNDROME AND TREATMENTS THEREFORE
  申请人：RETT SYNDROME RESEARCH TRUST

  公开号：US20160193231A1

  公开（公告）日：2016-07-07

  The present invention provides new strategies for the treatment of Rett Syndrome and other MECP2-associated disorders, including for the identification and/or characterization of useful therapeutic modalities and/or for the stratification of Rett Syndrome patients to identify those more or less likely to respond to a particular therapy. In some embodiments, the present invention defines certain components of metabolic pathways, and particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways, most particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways in the brain, as targets useful in the identification and/or characterization of potential Rett Syndrome treatment agents. Among other things, the present invention provides systems for identifying and/or characterizing such agents by contacting them with a system that comprises one or more such metabolic pathway components, and assessing their impact on presence, level, activity, and/or form of one or more indicators (e.g., components, products, and/or markers of the relevant pathway(s)).
• US7851199B2
  申请人：——

  公开号：US7851199B2

  公开（公告）日：2010-12-14